These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1149365)

  • 1. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.
    Mitchell JR; Thorgeirsson UP; Black M; Timbrell JA; Snodgrass WR; Potter WZ; Jollow HR; Keiser HR
    Clin Pharmacol Ther; 1975 Jul; 18(1):70-9. PubMed ID: 1149365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
    Mitchell JR; Zimmerman HJ; Ishak KG; Thorgeirsson UP; Timbrell JA; Snodgrass WR; Nelson SD
    Ann Intern Med; 1976 Feb; 84(2):181-92. PubMed ID: 766682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.
    Sarma GR; Immanuel C; Kailasam S; Narayana AS; Venkatesan P
    Am Rev Respir Dis; 1986 Jun; 133(6):1072-5. PubMed ID: 3717759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.
    Lauterburg BH; Smith CV; Todd EL; Mitchell JR
    J Pharmacol Exp Ther; 1985 Dec; 235(3):566-70. PubMed ID: 4078724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidation of hydrazine metabolites formed from isoniazid.
    Lauterburg BH; Smith CV; Todd EL; Mitchell JR
    Clin Pharmacol Ther; 1985 Nov; 38(5):566-71. PubMed ID: 3931954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoacetylhydrazine as a metabolite of isoniazid in man.
    Timbrell JA; Wright JM; Baillie TA
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):602-8. PubMed ID: 913027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.
    Peretti E; Karlaganis G; Lauterburg BH
    Eur J Clin Pharmacol; 1987; 33(3):283-6. PubMed ID: 3691615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid.
    Peretti E; Karlaganis G; Lauterburg BH
    J Pharmacol Exp Ther; 1987 Nov; 243(2):686-9. PubMed ID: 3681700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the role of acetylhydrazine in isoniazid hepatotoxicity.
    Timbrell JA
    Arch Toxicol Suppl; 1979; (2):1-8. PubMed ID: 288324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the effects of isoniazid on acetylhydrazine metabolism in vivo and in vitro.
    Timbrell JA; Wright JM
    Drug Metab Dispos; 1979; 7(4):237-40. PubMed ID: 39727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
    Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
    Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat.
    Nelson SD; Mitchell JR; Timbrell JA; Snodgrass WR; Corcoran GB
    Science; 1976 Sep; 193(4256):901-3. PubMed ID: 7838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the metabolism of [14C]acetylhydrazine in rats.
    Wright JM; Timbrell JA
    Drug Metab Dispos; 1978; 6(5):561-6. PubMed ID: 30606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for isoniazid (NIH)-induced liver dysfunction.
    Dickinson DS; Bailey WC; Hirschowitz BI; Soong SJ; Eidus L; Hodgkin MM
    J Clin Gastroenterol; 1981 Sep; 3(3):271-9. PubMed ID: 7288121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.
    Timbrell JA; Mitchell JR; Snodgrass WR; Nelson SD
    J Pharmacol Exp Ther; 1980 May; 213(2):364-9. PubMed ID: 6767840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.